

REMARKS

Continued prosecution and consideration of the claimed subject matter in the accompanying patent application is respectfully requested.

Claim 1 has been amended, and claims 5, 6 and 7 added. Claims 1-7 are in the case and are before the Examiner.

I. The Amendments

Claim 1 has been amended to better define the invention by reciting a preferred embodiment. Specific support for the present amendment can be found at least in the Abstract and in the text at paragraph [0024] of the published application No.2007/0249061. It is thus seen that there has been no addition of new matter.

The Action noted that claims 3 and 4 that depended from claim 1 were allowable if rewritten in independent form. Claims 1 and 3 have been rewritten together pursuant to the Examiner's helpful suggestion as new claim 5. Claim 3 was multiply dependent from both of claims 1 and 2, so prior claim 2 has been copied and rewritten as new claim 6 to depend from new claim 5. Claim 4 that originally depended from claim 3 has been copied and rewritten to depend from claim new claim 5 as new claim 7. It is again seen that no new matter has be added.

Replacement drawings for Figs. 2, 3, 5, 7, and 9 are enclosed.

II. The Action

A. Claim Objection

Claim 3 was objected to as containing the word "peptid". However, counsel's copies of the prior claims only contain the word "peptide" in claim 3. Counsel would appreciate

further assistance in locating the offending word so that it can be corrected.

B. Rejections Under 35 USC §103

Claims 1 and 2 were rejected as allegedly obvious from the disclosure of Kling et al. US Patent No. 7,105,508 (Kling) in view of the disclosures of Kumar et al. US Patent No. 6,218,136 (Kumar). The primary Kling teaching discloses use of a solid phase bound integrin $\alpha_v\beta_3$ as a substrate for competition assay between a test substance and a natural $\alpha_v\beta_3$ ligand vitronectin. The Kumar teaching is provided for its use of a fluorescence label rather than the peroxidase used by Kling. This basis for rejection cannot be agreed with and is respectfully traversed.

It is respectfully submitted that the present amendments have made this basis for rejection moot. More particularly, the present amendment to claim 1 added the recitation for the preferred embodiment of a calixarene coating on a protein chip. The use of such a coating is neither taught nor suggested in any of the relied-on art and as such, it submitted that the amended claims are patentable and this basis for rejection should be withdrawn.

III. Summary

Claim 1 has been amended and claims 5-7 added pursuant to the Examiner's helpful suggestions. The requested replacement drawings are enclosed. Each basis for objection or rejection has been dealt with and overcome or otherwise made moot.

It is thus believed that this application is in condition for allowance. An early notice to that effect is earnestly solicited.

No further fee or petition is believed to be necessary. However, should any further fee be needed, please charge our Deposit Account No. 23-0920, and deem this paper to be the required petition.

The Examiner is requested to phone the undersigned should any questions arise that can be dealt with over the phone to expedite this prosecution.

Respectfully submitted,

By



Edward P. Gamson, Reg. No. 29,381

WELSH & KATZ, LTD.
120 South Riverside Plaza, 22nd Floor
Chicago, Illinois 60606
Phone (312) 655-1500
Fax No. (312) 655-1501

Enclosures

Replacements for Figs. 2, 3, 5, 7, and 9.

June 23, 2008